
LIXTE Biotechnology Reports Promising Interim Results for LB-100 Combination Therapy in Ovarian Cancer Trial
LIXTE Biotechnology announced interim clinical trial results showing a 40% disease control rate for its LB-100 compound combined with dostarlimab in ovarian clear cell carcinoma, supporting continued investigation of this novel immunotherapy-enhancing approach.
Read full story






















